Published on 29/11/2025

Digital Readouts & Imaging Assays: Validation Considerations

The pharmaceutical and biotechnology industries are continually evolving, particularly concerning the validation of complex systems and assays. In this guide, we will explore crucial validation considerations for digital readouts and imaging assays, particularly as they pertain to biologics, advanced therapy medicinal products (ATMPs), and viral clearance. Our focus will be on key aspects such as planning, methodology, spiking studies, and compliance with regulatory guidelines.

Understanding Validation Frameworks for Digital Readouts and Imaging Assays

Validation of digital readouts and imaging assays is paramount in ensuring accuracy and reliability in biologics and ATMP development. These assays are pivotal for determining potency, identity, and ensuring compliance with stringent regulatory standards such as those outlined by the FDA, EMA, and MHRA. Understanding the framework for validation includes recognizing the purpose, scope, and the end-users of the assays.

• Purpose: The primary purpose of validation is to establish that the assay performs as intended, thereby ensuring the reliability of the data produced.
• Scope: Validation should encompass all aspects of the assay, including equipment, reagents, and processes involved in the analysis.
• End-User Consideration: Understanding the profiles of end-users of the assays will drive the technical specifications and acceptance criteria established in the validation process.

Regulatory guidance indicates that the validation process should include the generation of documentation that captures the objective evidence demonstrating a high degree of assurance that required attributes are met.

Planning for Viral Clearance Validation in Digital Assays

When planning for viral clearance validation specifically in the context of digital readouts and imaging assays, there are pivotal steps that need to be undertaken. A clear plan should be developed, addressing the specific requirements for spiking studies, utilizing closed systems, and single-use systems.

Initial Steps in Viral Clearance Validation Planning

The initial steps in planning for viral clearance validation should include:

• Identify Critical Quality Attributes (CQAs): For biologics, potency and identity CQAs must be rigorously outlined. These attributes dictate the performance characteristics of an assay.
• Develop a Comprehensive Validation Strategy: Define the scope of validation, including the specific viral pathogens of concern, the assay’s sensitivity and specificity, and the anticipated viral clearance levels required for regulatory compliance.
• Research Regulatory Guidelines: Familiarize yourself with relevant regulatory guidelines such as ICH Q5A(R2), which outlines expectations for viral safety in biological products.

Taking the time to develop a thorough plan mitigates risks and establishes a roadmap for executing spiking studies to assess the efficacy of viral clearance mechanisms employed in the assays.

Executing Spiking Studies Within the Validation Framework

Spiking studies are crucial for demonstrating the effectiveness of viral clearance. These studies typically involve the intentional introduction of viral contaminants to assess the system’s ability to eliminate them effectively.

Key Considerations in Spiking Studies

To effectively execute spiking studies, it’s essential to follow these guidelines:

• Selection of Viral Strains: Choose appropriate viral strains representative of the risk profile associated with the products being developed.
• Dose Levels: Define dose levels that are relevant to actual worst-case scenarios that could be encountered in commercial production.
• System Validation: Ensure the closed and single-use systems are properly validated to prevent contamination and maintain sterility throughout the spiking studies.

The outcome data from these spiking studies will contribute to an understanding of the robustness of the process and the effectiveness of the viral clearance strategy implemented across the assay methods.

Closed Systems and Their Role in Aseptic Processing

In recent years, closed systems have gained prevalence within aseptic processing, primarily due to their effectiveness in minimizing contamination risks. These systems are particularly important in the context of imaging assays for biologics and ATMP production. Aligning with the EMA guidelines on aseptic controls in Annex 1 is vital in maintaining compliance.

Benefits of Closed Systems in Validation

Utilizing closed systems presents numerous benefits, including:

• Minimizing Contamination Risk: Closed systems limit exposure to external contaminants and thus enhance the integrity of the assay.
• Consistency Across Studies: As closed systems maintain a sterile environment, they provide consistent conditions across all validation studies, which is fundamental for reproducibility.
• Regulatory Compliance: Meeting the increasing regulatory scrutiny around contamination risks is essential. Utilizing closed systems demonstrates a commitment to highest practice standards.

By integrating closed systems into your validation strategies, you can enhance the robustness of your methodologies while ensuring compliance with regulatory expectations.

Single-Use Systems: Innovations in Validation Approaches

Single-use systems have transformed the landscape of pharmaceutical manufacturing and analytical processes, particularly for biologics and ATMPs. These disposable systems help eliminate cross-contamination risks and improve operational flexibility.

Advantages of Single-Use Systems for Validation

Single-use systems provide several key advantages during the validation process:

• Reduction of Cleaning Validation Needs: As these systems are intended for one-time use, they significantly reduce the complexity associated with cleaning validation protocols.
• Streamlined Logistics: The use of single-use components simplifies logistics and inventory management, making it easier to adhere to stringent timelines required in the validation process.
• Adaptability and Scalability: Single-use systems offer great flexibility in experimentation and production scaling while ensuring consistent quality through controlled environments.

These systems are pivotal in modern biosafety strategies and play a vital role in ensuring the operational excellence and regulatory readiness of the validation framework.

Ensuring Chain of Identity Custody

As with any validation process, ensuring the chain of identity custody (CoIC) is paramount. This becomes critically important in the context of complex biologics and ATMP validation. The CoIC ensures traceability throughout the entire life cycle of the product under analysis.

Best Practices for Maintaining CoIC

Implementing best practices for maintaining a robust chain of identity custody involves:

• Documenting Every Step: Maintain detailed records at each stage of the assay process, including sample collection, handling, and analysis.
• Utilization of Barcoding Systems: Employ barcoding for samples to enhance traceability and minimize human error throughout the process.
• Training Personnel: Ensure all personnel involved in the assay process receive training on the importance of maintaining CoIC and best practices for recording data accurately.

Establishing solid CoIC practices protects the integrity of data generated from validation studies and may also assuage regulatory concerns regarding product safety and efficacy.

Tailoring PPQ and CPV Strategies for ATMPs

In the context of Process Performance Qualification (PPQ) and Continued Process Verification (CPV) for ATMPs, it is essential to tailor these strategies to accommodate the unique characteristics of the products involved. A collaborative approach that accounts for the specific attributes of an ATMP enhances the validation process.

Steps for Tailoring PPQ and CPV

To effectively tailor PPQ and CPV strategies, consider the following:

• Assess Specific Risks: Identify risks unique to the ATMPs in question, and adjust PPQ protocols accordingly to mitigate these risks.
• Dynamic Monitoring: Implement systems that allow for continuous monitoring and data collection throughout the production lifecycle of the ATMP.
• Collaboration with Stakeholders: Work closely with manufacturing, quality assurance, and regulatory teams to ensure that PPQ and CPV approaches are aligned with overarching quality objectives.

Tailored strategies in PPQ and CPV promote a thorough understanding of process performance and product quality over time, which is essential for regulatory compliance and operational excellence in producing biologics and ATMPs.

Conclusion: A Comprehensive Approach to Validation of Digital Assays

In conclusion, effective validation of digital readouts and imaging assays requires a meticulous and comprehensive approach, taking into consideration aspects such as viral clearance, closed and single-use systems, coherence with key CQAs, and regulatory compliance. By adhering to best practices and maintaining a strong plan throughout the validation process, industry professionals can ensure that complex assays meet and exceed regulatory expectations.

This structured approach to validation positions organizations favorably within the regulatory landscape and facilitates the successful development and commercialization of innovative biologics and ATMPs.